Clinical Trial Update: Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma [EARLY_Phase 1]

View source ↗

Summary

This document describes an early-phase (Phase 1) clinical trial evaluating anti-CD20/CD30 CAR-T cells in patients with relapsed or refractory lymphoma, currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Anti-CD20/CD30 CAR-T cells (CAR-T cells targeting CD20 and CD30)

Snippet

Sponsor: Shanghai First Song Biotechnology Co., LTD | Conditions: Relapsed/Refractory Lymphoma | EARLY_Phase 1 | Status: RECRUITING